Tag Archives: life sciences

Hot Investor Mandate: Singapore-Based PE Firm Invests Up to $20M in All Areas of Life Sciences with Potential for Global Growth, Open to Any Stage of Development

12 Jul

A private equity and corporate finance advisory firm is headquartered in Singapore with a global presence. The firm makes global investments into life science and healthcare companies as well as services related to healthcare. The firm acts as a lead investor and utilizes their network to seek out other co-investors. Typical deal size is $0.5m to $20m. The firm will occasionally seek distribution rights for international investments.

The firm is interested in therapeutics, medical devices, diagnostics, healthcare IT, healthcare services, biotech, R&D services and suppliers and engineering companies. The firm is both stage and indication agnostic and has no revenue requirement. The firm has no flexible investment criteria but the East West Axis is very important as the firm is not interested in companies that are restricted to one country. The firm looks for companies with a multinational, global component.

The firm is flexible with their management team requirements. The firm is open to bringing in their own talent to assist with management and have supported scientists in becoming successful entrepreneurs. The firm is a value-added investor driven by opportunity. The firm takes a board seat when making investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Investment Firm with Offices in USA, China, and India Invests Opportunistically in Life Sciences, with Strongest Interest in Novel Medical Devices and Cardiovascular Diseases

28 Jun

Founded in 2015, is a venture capital firm with offices in Boston, China, and India currently manages a fund with $125 million and is actively seeking investment opportunities across a wide range of industries. A significant allocation of the fund is dedicated to healthcare investments, while the rest of the fund will focus on investing in automation/robotics companies and relations to healthcare. On average, the size of investment is $2.5M. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm can participate anywhere from Seed to Series B. The firm is willing to both lead and co-invest in companies located around the globe, with a preference in US, China, and Germany. The firm plans to make 6-8 investments per year but is flexible. The firm is actively seeking new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of sectors and indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in medical devices and cardiovascular diseases. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase III. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases, but the firm prefers to have board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Venture Capital Firm with Strong Connections to China Seeks to Invest in Global, Early-Stage Biotech Companies with Opportunistic Outlook

21 Jun

A venture capital firm founded in 2014 has an office in the West Coast with its parent company based in Hangzhou, China. The firm currently has invested in over 39 companies across a wide variety of sectors including biotech, IoT, AI, etc. The firm’s strong connection with Chinese partners enables the firm to support companies with market entry in China. The firm is currently allocating out of its first fund of $20M and prefers to participate in seed/pre-series A financing rounds with check sizes of no larger than $500K.

The firm is currently raising a second fund with a target size of $50M, through which the firm hopes to invest more capital in later rounds (i.e. Series A to B) and provide follow on investments to portfolio companies. Through the second fund, the firm is also seeking to expand their interests in diagnostics, digital health, and novel therapeutics. Early in 2018, the firm has launched an accelerator program to support the growth of early-stage companies in the sectors mentioned above and provide these companies with valuable resources. The firm seeks investment opportunities globally.

The firm is opportunistic and will seek companies in all parts of the life sciences space: therapeutics, medical devices, diagnostics, healthcare IT, etc. The firm has not invested in therapeutic products so far but is actively seeking new opportunities in the biopharma space, focusing on pre-clinical to phase I assets. The firm focuses on early-stage deals and will consider pre-FDA device products. The firm is open to companies developing products in all indications.

The firm seeks to work with privately owned companies with experienced management teams with a track record of success. The firm likes to see companies with intentions of entering the China market as the firm has a network of resources to support this, but this is not a requirement. The firm generally acts as the co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Germany-Based CVC with a Global Presence Invests in Innovative Medical Technologies Globally, Including Imaging & PoC and In Vitro Diagnostics

7 Jun

A corporate venture firm is headquartered in Munich, Germany, with additional offices worldwide. The fund invests in medical technology companies that are strategically relevant to the corporate’s interests. Investments in equity rounds range from $1-5 million and are made worldwide.

The firm’s primary focuses within healthcare are medical imaging (including both equipment and software) and diagnostics (particularly point of care diagnostics and molecular diagnostics). In these sectors, the firm focuses on products used in a hospital setting. The firm also invests in digital health solutions that add value to imaging and diagnostics, such as data-as-a-service products. The firm is potentially interested in medical robotics. The firm will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The firm generally does not attach strategic rights to an investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI Boston Summer, June 4, 2018 – Program Guide Is Here!

31 May

By Nono Hu, Director of Marketing, LSN

In 4 days, The Redefining Early Stage Investments (RESI) Conference will kick off a bustling week for the global healthtech industry in Boston. At RESI Boston, over 300 investors will be under one roof in search of compelling connections with early stage companies.

Check out the program guide now to plan for a productive day at RESI packed with partnering meetings, innovative technologies, and up-to-date investment knowhow.

See you at RESI on June 4th at the Boston Marriott Copley Place!

Hot Investor Mandate 1: Family Office Creates Investment Arm for Medical Device Companies Based in the U.S.

10 May

A family office arm specializes in investing in and operating medical device companies in which it holds a controlling interest. The firm looks to invest in early and seed stage companies with the goal of investing in 1-2 companies per year to add to its portfolio.

The firm looks to invest in medical device companies that are still in development. The firm prefers technologies subject to the FDA 510(k) pathway, but will consider PMA/combination device and therapeutics if the technology is extremely disruptive. The investors are agnostic with regards to subsector and indication. Current portfolio companies include surgical tools for cardiovascular interventions, consumer health electronics, hospital hardware and therapeutic delivery devices for multiple clinical applications.

The firm looks to invest in companies with great technology that need operational expertise to help advance the technology to market with the goal of leveraging its internal management team for execution of product development, regulatory, and commercial strategy.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Venture Firm Seeking Cellular Engineering Technologies for Diagnostics, Devices, and Therapeutics

10 May

A venture fund focusing on the frontiers of the intersection of science and technology looks for companies that are changing the market standards through innovative approaches. The firm is interested in US-based companies and generally invests in seed-series A rounds, typically when less than $5m is being raised. The firm invests in pre-clinical/in development technologies but prefers there to be proof-of-concept data. For medical devices, the firm will consider devices in the 510k regulatory pathway. The firm will generally invest between $250,000-1M, and will often connect companies to larger funds for later capital raises.

The firm is agnostic to sector and indication, and will also consider platform technologies. However, the firm is looking for companies that use DNA and cellular engineering technologies for diagnostics and therapeutics. The firm is not interested in standard therapeutics approaches such as small molecules. For medical devices, the firm is looking for devices that change the paradigms of care, solving an unmet need with a unique approach.

The firm does not require a board seat when investing. Rather, the firm will be as involved as necessary to help the company succeed, whether through personal intervention or through a connection to an external expert.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: